LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now?

Alkermes is presented as the more balanced pick versus Liquidia, supported by a diversified commercial portfolio, $136.1 million of Lumryz revenue in the first half of 2026 following the Avadel acquisition, and $691.6 million in cash and investments. Liquidia's Yutrepia launch has driven its fourth consecutive profitable quarter and consensus forecasts for 340.72% 2026 sales growth, but its 2026 EPS estimate fell to $2.57 from $3.02 and it faces product concentration and an unresolved United Therapeutics patent dispute. LQDA shares are up 105% year-to-date versus 45.8% for ALKS, but trade at 6.21x forward sales versus ALKS at 3.60x.

Analysis

The cleaner relative-value expression is ALKS versus LQDA, not an outright biotech-beta call. LQDA’s premium revenue multiple embeds sustained conversion of prescriptions into durable, reimbursed patients and near-perfect execution from a single franchise; downward earnings revisions indicate that launch economics, rather than demand alone, are now the key debate. Any remedy that reduces PH-ILD economics would have an outsized effect on LQDA’s terminal-value assumptions, while UTHR would gain protection for its inhaled-treprostinil cash-flow pool and pricing architecture.

ALKS has a nearer-term accounting overhang from acquisition-related costs, but this creates an unusual setup: investors may be valuing a temporary earnings trough while the acquired sleep franchise and broader neuroscience platform expand revenue diversification. Over 6-18 months, successful integration can shift the debate from acquisition dilution to operating leverage and pipeline optionality; failure would show up first in Lumryz persistence, sales-force efficiency, and 2027 loss estimates rather than in headline revenue. BIIB has modest indirect upside only through stable Vumerity partner economics, not enough for a standalone trade.

Contrarian view: the market may be too focused on LQDA’s binary legal risk and too dismissive of its potential to preserve access through royalties rather than an injunction. That outcome could trigger a sharp relief rally, but it would not solve concentration risk or justify ignoring decelerating estimate momentum. Conversely, ALKS’ apparent diversification is partly acquisition-created, so its rerating requires proof that the acquired asset grows without cannibalizing capital allocated to internal orexin programs.

Key Decisions for Investors

• Initiate a 3-6 month market-neutral pair: long ALKS / short LQDA, sized beta-neutral. Target 15-25% relative outperformance as ALKS derisks integration while LQDA’s valuation absorbs legal and estimate risk; cover the LQDA short if the litigation outcome explicitly preserves PH-ILD commercialization without material royalties or volume restrictions.
• For event-risk accounts, replace an outright LQDA short with a 3-6 month put spread funded by an out-of-the-money call sale only after confirming the legal-decision timetable and borrow availability. The missing critical data are remedy probabilities and LQDA’s post-remedy gross-margin sensitivity; without them, avoid naked short exposure into the ruling.
• Accumulate ALKS on post-earnings weakness over the next 1-3 months, contingent on maintained 2027 consensus estimates and evidence of stable Lumryz refill/persistence trends. Thesis fails if integration spending extends beyond guidance or management cuts acquired-product growth expectations; initial upside is multiple normalization toward more diversified specialty-pharma peers.
• Monitor UTHR as a tactical long only if the legal ruling validates meaningful exclusivity or imposes economically material LQDA constraints. A favorable ruling may be partly priced in, so require confirmation through maintained Tyvaso guidance and absence of reimbursement-driven share leakage before adding exposure.